Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Bulai Livideanu Cridtina
Institution:
Centre Hospitalier Universitaire de Toulouse
Observed institution:
Centre Hospitalier Universitaire de Toulouse
OpenAlex ID:
A5115010943
Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis
2024
·
Lindsay A.M. Rein
, Daniel J. DeAngelo
, et al.
·
Blood
·
4
Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)
2024
·
Daniel J. DeAngelo
, Jason Gotlib
, et al.
·
Blood
·
4
Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis
2024
·
Isaac Goncalves
, Stephen Fuller
, et al.
·
Blood
PDF
Show more works
View as search
Works count:
3
Citation count:
8
H-index:
2
I10-index:
Year
Topic
Type
